HAWTHORNE, N.Y.--(BUSINESS WIRE)--Taro Pharmaceutical Industries Ltd. (“Taro,” NASDAQ: TARO) reported today that Taro Pharmaceuticals (UK) Limited (“Taro UK”), its affiliate in the United Kingdom, has been granted a marketing authorization for Etopan XL Tablets 600 mg, Etodolac (“Etopan XL”) by the Medicines and Healthcare Products Regulatory Agency, the UK equivalent of the U.S. Food and Drug Administration.
